Infantile Spasm (West Syndrome) - Pipeline Review, H1 2016

  • ID: 3774185
  • Report
  • 55 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • INSYS Therapeutics, Inc.
  • Novartis AG
  • Retrophin Inc.
  • MORE
Infantile Spasm (West Syndrome) - Pipeline Review, H1 2016

Summary

‘Infantile Spasm (West Syndrome) - Pipeline Review, H1 2016’, provides an overview of the Infantile Spasm (West Syndrome) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Infantile Spasm (West Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Infantile Spasm (West Syndrome) and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Infantile Spasm (West Syndrome)
- The report reviews pipeline therapeutics for Infantile Spasm (West Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Infantile Spasm (West Syndrome) therapeutics and enlists all their major and minor projects
- The report assesses Infantile Spasm (West Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Infantile Spasm (West Syndrome)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Infantile Spasm (West Syndrome)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Infantile Spasm (West Syndrome) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • INSYS Therapeutics, Inc.
  • Novartis AG
  • Retrophin Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Infantile Spasm (West Syndrome) Overview

Therapeutics Development

Pipeline Products for Infantile Spasm (West Syndrome) - Overview

Infantile Spasm (West Syndrome) - Therapeutics under Development by Companies

Infantile Spasm (West Syndrome) - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Infantile Spasm (West Syndrome) - Products under Development by Companies

Infantile Spasm (West Syndrome) - Companies Involved in Therapeutics Development

Anavex Life Sciences Corp.

Catalyst Pharmaceuticals, Inc.

INSYS Therapeutics, Inc.

Novartis AG

Retrophin Inc.

Infantile Spasm (West Syndrome) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

ANAVEX-273 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AVL-5189 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

cannabidiol - Drug Profile

Product Description

Mechanism of Action

R&D Progress

cosyntropin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

cosyntropin ER - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CPP-115 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Infantile Spasm (West Syndrome) - Recent Pipeline Updates

Infantile Spasm (West Syndrome) - Dormant Projects

Infantile Spasm (West Syndrome) - Product Development Milestones

Featured News & Press Releases

May 18, 2016: Anavex Announces Positive Preclinical Data for ANAVEX 2-73 in Infantile Spasms

Feb 09, 2016: Insys Therapeutics Enrolls First Patient in Phase II Study for the Treatment of Infantile Spasms Using Pharmaceutical CBD

Dec 16, 2015: Catalyst Pharmaceuticals Announces Top-Line Results in Phase 1(b) Trial of CPP-115

Aug 04, 2015: Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol for the Treatment of Infantile Spasms

Nov 24, 2014: Catalyst Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application for the Reduction or Elimination of Visual Field Defects by Treating Patients With CPP-115

Sep 02, 2014: Catalyst Pharmaceutical Partners Initiates Phase 1(b) Safety and Tolerance Study for CPP-115

Nov 18, 2013: Catalyst Pharmaceutical Partners Announces Publication of Preclinical Proof-of-Principle of CPP-115 Efficacy in Suppressing Infantile Spasms in Epilepsia

Feb 13, 2012: Catalyst Receives Orphan Medicinal Product Designation In EU For CPP-115 To Treat West Syndrome

Jan 31, 2012: Catalyst Pharmaceutical Partners To Present CPP-115 Progress At 2012 Epilepsy Pipeline Update Conference

Dec 15, 2011: Catalyst Announces Scientific Paper Regarding CPP-115 For Treatment Of Cocaine Addiction Accepted For Publication In Journal Of Medicinal Chemistry

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Infantile Spasm (West Syndrome), H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Infantile Spasm (West Syndrome) - Pipeline by Anavex Life Sciences Corp., H1 2016

Infantile Spasm (West Syndrome) - Pipeline by Catalyst Pharmaceuticals, Inc., H1 2016

Infantile Spasm (West Syndrome) - Pipeline by INSYS Therapeutics, Inc., H1 2016

Infantile Spasm (West Syndrome) - Pipeline by Novartis AG, H1 2016

Infantile Spasm (West Syndrome) - Pipeline by Retrophin Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Infantile Spasm (West Syndrome) Therapeutics - Recent Pipeline Updates, H1 2016

Infantile Spasm (West Syndrome) - Dormant Projects, H1 2016

List of Figures

Number of Products under Development for Infantile Spasm (West Syndrome), H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Anavex Life Sciences Corp.
Catalyst Pharmaceuticals, Inc.
INSYS Therapeutics, Inc.
Novartis AG
Retrophin Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll